COMMUNIQUÉS West-GlobeNewswire

MediPharm Labs Signs Large Multi-Year Cannabis Extraction Agreement With TerrAscend Marking Strong Start to 2019

08/01/2019 - 12:31

TORONTO, Jan. 08, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS; OTCQB: MLCPF) (the “ Company ” or “ MediPharm Labs ”), a specialized, research-driven cannabis extraction business, fully licensed under the [...]

Corrected Financial Calendar 2019

08/01/2019 - 12:13

January 8, 2019 Announcement no. 1 Corrected Financial Calendar 2019 DATE 2019 DESCRIPTION January 25, 2019 Quiet Period prior to the Annual Report begins (4 weeks) February 1, 2019 Deadline for shareholder proposals - [...]

Transactions in relation to share buyback program

08/01/2019 - 11:00

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Vistin Pharma ASA : Update on Energy Trading business

08/01/2019 - 08:42

(Oslo, Norway, 8 January 2019) The Board of Directors of Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) has conducted a strategic review of the Energy Trading business following the development in the energy markets. [...]

Immuron Receives $1.19M R&D Tax Concession Refund

08/01/2019 - 08:32

MELBOURNE, Australia, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development Income Tax [...]

Curetis’ Subsidiary Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test

08/01/2019 - 08:00

Curetis’ Subsidiary Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test Ares Genetics to start EUR 1.3 million TRIPLE-A development project co-funded by Vienna Business Agency Initiates [...]

Update on Admission

08/01/2019 - 08:00

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”) Subscription to Raise $25m Oxford, UK, and Cambridge, MA, US, 8 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic [...]

Scheme becomes effective

08/01/2019 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR [...]

NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY TREATMENT

08/01/2019 - 07:31

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY TREATMENT Paris and Boston, January 8, 2019 - 7 [...]

NÉOVACS REÇOIT UN FINANCEMENT DE L'ANR - L'AGENCE NATIONALE DE LA RECHERCHE - POUR LE DÉVELOPPEMENT DE L'IL-4/IL-13 KINOÏDE DANS L'ALLERGIE

08/01/2019 - 07:31

COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS REÇOIT UN FINANCEMENT DE L'ANR - L'AGENCE NATIONALE DE LA RECHERCHE - POUR LE DÉVELOPPEMENT DE L'IL-4/IL-13 KINOÏDE DANS L'ALLERGIE Paris et [...]

Nicox Reaches 50% Enrollment Threshold in U.S. Phase 2 Study with NCX 470 Ahead of Schedule

08/01/2019 - 07:31

Press Release Nicox Reaches 50% Enrollment Threshold in U.S. Phase 2 Study with NCX 470 Ahead of Schedule ............................................... January 8, 2019 - release at 7:30 am CET Sophia Antipolis, France [...]

Nicox atteint plus tôt que prévu le seuil de 50% de recrutement dans l'étude clinique de phase 2 avec le NCX 470 aux Etats-Unis

08/01/2019 - 07:31

Communiqué de presse Nicox atteint plus tôt que prévu le seuil de 50% de recrutement dans l'étude clinique de phase 2 avec le NCX 470 aux Etats-Unis ................................................. 8 janvier 2019 - [...]

Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease

08/01/2019 - 07:15

Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are triggered by multi-cell adhesion [...]

Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco

08/01/2019 - 01:44

NEW YORK and MELBOURNE, Australia, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), world leader in the development and commercialization of cellular medicines, today reported on commercial [...]

Scheme becomes effective

08/01/2019 - 01:09

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR [...]

Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility

08/01/2019 - 00:35

NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, [...]

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan

08/01/2019 - 00:00

LA JOLLA, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]

Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering

07/01/2019 - 23:39

CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today [...]

Canopy Rivers Announces $80 Million Bank Debt Facility at PharmHouse

07/01/2019 - 23:19

TORONTO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (“ Canopy Rivers ” or the “ Company ”) (TSXV: RIV) today announced that its 49%-owned joint venture PharmHouse Inc. (“ PharmHouse ”) has entered into a [...]